Patent details

Basic Information

Publication number:

EP2266572

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP101736726

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

pyrimidylaminobenzamide derivative for use in the treatment of a TEL-PDGFRß-induced myeloproliferative disease

French Title of Invention:

Dérivé de pyrimidylaminobenzamide pour utilisation dans le traitement d'un syndrome myéloprolifératif induit par TEL-PDGFRß

German Title of Invention:

Pyrimidylaminobenzamid Derivate zur Verwendung in der Behandlung einer TEL-PDGFRß induzierten myeloproliferativen Erkrankung

SPC Number:

Dates

Filing date:

02/05/2006

Grant date:

21/09/2016

EP Publication Date:

21/09/2016

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

29/12/2010

EP B1 Publication Date:

21/09/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

02/05/2017

Expiration date:

02/05/2026

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

02/05/2006

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:

Manley Paul W.

Address:

Switzerland (CH)

2

Name:

Fabbro Doriano

Address:

Switzerland (CH)

3

Name:

Mestan Juergen

Address:

Germany (DE)

Priority

Priority Number:

676751 P

Priority Date:

02/05/2005

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 31/506;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages